Protocol of a prospective community-based study about the onset and course of depression in a nationally representative cohort of adults in China: the China Depression Cohort Study-I.
China
Cohort study
Community-based
Depression
Prospective
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
24 08 2023
24 08 2023
Historique:
received:
23
04
2023
accepted:
16
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Depression is the second most important cause of disability worldwide. Reducing this major burden on global health requires a better understanding of the etiology, risk factors, and course of the disorder. With the goal of improving the prevention, recognition, and appropriate management of depressive disorders in China, the China Depression Cohort Study will establish a nationally representative sample of at least 85,000 adults (the China Depression Cohort Study-I) and 15,000 middle school students (the China Depression Cohort Study-II) and follow them over time to identify factors that influence the onset, characteristics, and course of depressive disorders. This protocol describes the China Depression Cohort Study-I. A multistage stratified random sampling method will be used to identify a nationally representative community-based cohort of at least 85,000 adults (i.e., ≥ 18 years of age) from 34 communities in 17 of mainland China's 31 provincial-level administrative regions. Baseline data collection includes 1) demographic, social and clinical data, 2) diagnostic information, 3) biological samples (i.e., blood, urine, hair), 4) brain MRI scans, and 5) environmental data (e.g., community-level metrics of climate change, air pollution, and socio-economic characteristics). Baseline findings will identify participants with or without depressive disorders. Annual reassessments will monitor potential risk factors for depression and identify incident cases of depression. Cox Proportional-Hazards Regression, Network analysis, Disease trajectory modelling, and Machine learning prediction models will be used to analyze the collected data. The study's main outcomes are the occurrence of depressive disorders; secondary outcomes include adverse behaviors (e.g., self-harm, suicide), the recurrence of depression and the incidence other mental disorders. The China Depression Cohort Study-I will collect a comprehensive, nationally representative set of individual-level and community-level variables over time. The findings will reframe the understanding of depression from a 'biology-psychology-society' perspective. This perspective will improve psychiatrists' understanding of depression and, thus, promote the development of more effective subgroup-specific antidepressant drugs and other interventions based on the new biomarkers and relationships identified in the study. The protocol has been registered on the Chinese Clinical Trial Registry (No. ChiCTR2200059016).
Sections du résumé
BACKGROUND
Depression is the second most important cause of disability worldwide. Reducing this major burden on global health requires a better understanding of the etiology, risk factors, and course of the disorder. With the goal of improving the prevention, recognition, and appropriate management of depressive disorders in China, the China Depression Cohort Study will establish a nationally representative sample of at least 85,000 adults (the China Depression Cohort Study-I) and 15,000 middle school students (the China Depression Cohort Study-II) and follow them over time to identify factors that influence the onset, characteristics, and course of depressive disorders. This protocol describes the China Depression Cohort Study-I.
METHODS
A multistage stratified random sampling method will be used to identify a nationally representative community-based cohort of at least 85,000 adults (i.e., ≥ 18 years of age) from 34 communities in 17 of mainland China's 31 provincial-level administrative regions. Baseline data collection includes 1) demographic, social and clinical data, 2) diagnostic information, 3) biological samples (i.e., blood, urine, hair), 4) brain MRI scans, and 5) environmental data (e.g., community-level metrics of climate change, air pollution, and socio-economic characteristics). Baseline findings will identify participants with or without depressive disorders. Annual reassessments will monitor potential risk factors for depression and identify incident cases of depression. Cox Proportional-Hazards Regression, Network analysis, Disease trajectory modelling, and Machine learning prediction models will be used to analyze the collected data. The study's main outcomes are the occurrence of depressive disorders; secondary outcomes include adverse behaviors (e.g., self-harm, suicide), the recurrence of depression and the incidence other mental disorders.
DISCUSSION
The China Depression Cohort Study-I will collect a comprehensive, nationally representative set of individual-level and community-level variables over time. The findings will reframe the understanding of depression from a 'biology-psychology-society' perspective. This perspective will improve psychiatrists' understanding of depression and, thus, promote the development of more effective subgroup-specific antidepressant drugs and other interventions based on the new biomarkers and relationships identified in the study.
TRAIL REGISTRATION
The protocol has been registered on the Chinese Clinical Trial Registry (No. ChiCTR2200059016).
Identifiants
pubmed: 37620799
doi: 10.1186/s12889-023-16542-6
pii: 10.1186/s12889-023-16542-6
pmc: PMC10463817
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1617Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Lancet Psychiatry. 2019 Mar;6(3):211-224
pubmed: 30792114
Environ Health Perspect. 2019 Dec;127(12):126002
pubmed: 31850801
Sleep. 2014 Feb 01;37(2):239-44
pubmed: 24497652
Int J Methods Psychiatr Res. 2010 Sep;19(3):125-41
pubmed: 20641046
J Affect Disord. 2019 Jun 15;253:292-302
pubmed: 31077972
BMC Med Inform Decis Mak. 2019 Dec 21;19(1):281
pubmed: 31864346
Environ Health Perspect. 2022 Feb;130(2):27006
pubmed: 35157500
Am J Psychiatry. 2020 May 01;177(5):447-453
pubmed: 32340466
Cancer Med. 2021 Aug;10(16):5653-5660
pubmed: 34309238
BMJ Open. 2019 Mar 1;9(3):e024939
pubmed: 30826765
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
J Affect Disord. 2018 Aug 1;235:105-113
pubmed: 29655070
Lancet Public Health. 2020 Dec;5(12):e650-e660
pubmed: 33271078
Neurotherapeutics. 2018 Jan;15(1):36-59
pubmed: 29134359
Int J Environ Res Public Health. 2020 Aug 25;17(17):
pubmed: 32854453
Int J Methods Psychiatr Res. 2017 Sep;26(3):
pubmed: 27766715
Psychiatr Hung. 2019;34(4):359-368
pubmed: 31767796
BMC Res Notes. 2011 Dec 05;4:524
pubmed: 22142532
Annu Rev Public Health. 2019 Apr 1;40:239-259
pubmed: 30633709
Lancet Psychiatry. 2022 Feb;9(2):137-150
pubmed: 35026139
Psychiatriki. 2021 Dec;32(Supplement I):11-14
pubmed: 34990376
Popul Health Metr. 2005 Mar 16;3(1):3
pubmed: 15769298
Lancet Psychiatry. 2021 May;8(5):373-386
pubmed: 33740410
Clin Psychol Rev. 2021 Feb;83:101943
pubmed: 33271426
Sci Total Environ. 2020 Jan 20;701:134721
pubmed: 31715478
J Am Acad Child Adolesc Psychiatry. 2020 Jul;59(7):842-855
pubmed: 31676392
Environ Health Perspect. 2022 Feb;130(2):25001
pubmed: 35171017
J Affect Disord. 2021 Mar 1;282:289-298
pubmed: 33418381
Nephron Clin Pract. 2009;113(3):c214-7
pubmed: 19690438
BMC Pregnancy Childbirth. 2019 Nov 27;19(1):444
pubmed: 31775666
Depress Anxiety. 2018 Sep;35(9):861-867
pubmed: 29878482
Int J Environ Res Public Health. 2021 Sep 30;18(19):
pubmed: 34639621
Lancet. 2009 Jun 13;373(9680):2041-53
pubmed: 19524780
Front Public Health. 2020 Oct 30;8:580757
pubmed: 33194985
J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11
pubmed: 34459676
Int J Methods Psychiatr Res. 2023 Mar;32(1):e1942
pubmed: 36054177
Environ Res. 2023 Aug 15;231(Pt 3):116303
pubmed: 37268208
Am J Psychiatry. 2021 Jun;178(6):522-529
pubmed: 33985349
Front Public Health. 2022 Jun 09;10:821881
pubmed: 35757622
Asian J Psychiatr. 2008 Dec;1(2):51-5
pubmed: 23050998
BMJ Open. 2020 May 26;10(5):e032580
pubmed: 32461290
Z Psychosom Med Psychother. 2020 Dec;66(4):402-417
pubmed: 33284065
JAMA Netw Open. 2020 Feb 5;3(2):e1921043
pubmed: 32049295
J Affect Disord. 2018 Dec 1;241:206-215
pubmed: 30130686
Lancet. 2002 Jan 26;359(9303):341-5
pubmed: 11830217
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326